624 related articles for article (PubMed ID: 27544072)
21. Effect of C7 modifications on benzothiadiazine-1,1-dioxide derivatives on their inhibitory activity and selectivity toward aldose reductase.
Zhang S; Chen X; Parveen S; Hussain S; Yang Y; Jing C; Zhu C
ChemMedChem; 2013 Apr; 8(4):603-13. PubMed ID: 23136050
[TBL] [Abstract][Full Text] [Related]
22. (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors.
Kucerova-Chlupacova M; Halakova D; Majekova M; Treml J; Stefek M; Soltesova Prnova M
Chem Biol Interact; 2020 Dec; 332():109286. PubMed ID: 33038328
[TBL] [Abstract][Full Text] [Related]
23. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives.
Celestina SK; Sundaram K; Ravi S
Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051
[TBL] [Abstract][Full Text] [Related]
24. Pyridothiadiazine derivatives as aldose reductase inhibitors having antioxidant activity.
Zhu S; Zhang S; Hao X; Qin X; Parveen S; Yang S; Ma B; Zhu C
J Enzyme Inhib Med Chem; 2016; 31(sup1):126-130. PubMed ID: 27153454
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of indole-substituted thiosemicarbazones as an aldose reductase inhibitor: an
Shehzad MT; Khan A; Halim SA; Hameed A; Imran A; Iqbal J; Ullah A; Asari A; Khan S; Shafiq Z; Al-Harrasi A
Future Med Chem; 2021 Jul; 13(14):1185-1201. PubMed ID: 34148377
[No Abstract] [Full Text] [Related]
26. Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications.
Vyas B; Choudhary S; Singh PK; Kumar M; Verma H; Singh M; Malik AK; Silakari O
Bioorg Chem; 2020 Mar; 96():103570. PubMed ID: 31978681
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and molecular modeling of novel non-sulfonylureas as hypoglycemic agents and selective ALR2 inhibitors.
Salem MG; Aziz YMA; Elewa M; Elshihawy HA; Said MM
Bioorg Med Chem; 2019 Aug; 27(15):3383-3389. PubMed ID: 31221611
[TBL] [Abstract][Full Text] [Related]
28. Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity.
Chen H; Zhang X; Zhang X; Fan Z; Liu W; Lei Y; Zhu C; Ma B
Bioorg Med Chem; 2020 Oct; 28(20):115699. PubMed ID: 33069078
[TBL] [Abstract][Full Text] [Related]
29. Designing of acyl sulphonamide based quinoxalinones as multifunctional aldose reductase inhibitors.
Ji Y; Chen X; Chen H; Zhang X; Fan Z; Xie L; Ma B; Zhu C
Bioorg Med Chem; 2019 Apr; 27(8):1658-1669. PubMed ID: 30858026
[TBL] [Abstract][Full Text] [Related]
30. Ponalrestat: a potent and specific inhibitor of aldose reductase.
Ward WH; Sennitt CM; Ross H; Dingle A; Timms D; Mirrlees DJ; Tuffin DP
Biochem Pharmacol; 1990 Jan; 39(2):337-46. PubMed ID: 2105733
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationship studies of phenolic hydroxyl derivatives based on quinoxalinone as aldose reductase inhibitors with antioxidant activity.
Hao X; Han Z; Li Y; Li C; Wang X; Zhang X; Yang Q; Ma B; Zhu C
Bioorg Med Chem Lett; 2017 Feb; 27(4):887-892. PubMed ID: 28109789
[TBL] [Abstract][Full Text] [Related]
32. Biological effects of bis-hydrazone compounds bearing isovanillin moiety on the aldose reductase.
Yapar G; Esra Duran H; Lolak N; Akocak S; Türkeş C; Durgun M; Işık M; Beydemir Ş
Bioorg Chem; 2021 Dec; 117():105473. PubMed ID: 34768205
[TBL] [Abstract][Full Text] [Related]
33. Determination of the inhibition profiles of pyrazolyl-thiazole derivatives against aldose reductase and α-glycosidase and molecular docking studies.
Demir Y; Taslimi P; Koçyiğit ÜM; Akkuş M; Özaslan MS; Duran HE; Budak Y; Tüzün B; Gürdere MB; Ceylan M; Taysi S; Gülçin İ; Beydemir Ş
Arch Pharm (Weinheim); 2020 Dec; 353(12):e2000118. PubMed ID: 32761859
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold.
Chen X; Yang Y; Ma B; Zhang S; He M; Gui D; Hussain S; Jing C; Zhu C; Yu Q; Liu Y
Eur J Med Chem; 2011 May; 46(5):1536-44. PubMed ID: 21367494
[TBL] [Abstract][Full Text] [Related]
35. Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
Papastavrou N; Chatzopoulou M; Ballekova J; Cappiello M; Moschini R; Balestri F; Patsilinakos A; Ragno R; Stefek M; Nicolaou I
Eur J Med Chem; 2017 Apr; 130():328-335. PubMed ID: 28259841
[TBL] [Abstract][Full Text] [Related]
36. Phenolic 4-hydroxy and 3,5-dihydroxy derivatives of 3-phenoxyquinoxalin-2(1H)-one as potent aldose reductase inhibitors with antioxidant activity.
Zou Y; Qin X; Hao X; Zhang W; Yang S; Yang Y; Han Z; Ma B; Zhu C
Bioorg Med Chem Lett; 2015 Sep; 25(18):3924-7. PubMed ID: 26227780
[TBL] [Abstract][Full Text] [Related]
37. Identification of new potent inhibitor of aldose reductase from Ocimum basilicum.
Bhatti HA; Tehseen Y; Maryam K; Uroos M; Siddiqui BS; Hameed A; Iqbal J
Bioorg Chem; 2017 Dec; 75():62-70. PubMed ID: 28917123
[TBL] [Abstract][Full Text] [Related]
38. Molecular modelling and synthesis of spiroimidazolidine-2,4-diones with dual activities as hypoglycemic agents and selective inhibitors of aldose reductase.
Salem MG; Abdel Aziz YM; Elewa M; Elshihawy HA; Said MM
Bioorg Chem; 2018 Sep; 79():131-144. PubMed ID: 29751319
[TBL] [Abstract][Full Text] [Related]
39. Structure-based optimization of aldose reductase inhibitors originating from virtual screening.
Eisenmann M; Steuber H; Zentgraf M; Altenkämper M; Ortmann R; Perruchon J; Klebe G; Schlitzer M
ChemMedChem; 2009 May; 4(5):809-19. PubMed ID: 19301313
[TBL] [Abstract][Full Text] [Related]
40. Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.
Kumar M; Choudhary S; Singh PK; Silakari O
Future Med Chem; 2020 Jul; 12(14):1327-1358. PubMed ID: 32602375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
